Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Open accessThe DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cryopyrin-associated periodic syndrome (CAPS) is a rare inherited inflammatory disease associated with overproduction of interleukin-1. Canakinumab is a human anti-interleukin-1beta monoclonal antibody. METHODS: We performed a three-part, 48-week, double-blind, placebo-controlled, randomized withdrawal study of canakinumab in patients with CAPS. In part 1, 35 patients received 150 mg of canakinumab subcutaneously. Those with a complete response to treatment entered part 2 and were randomly assigned to receive either 150 mg of canakinumab or placebo every 8 weeks for up to 24 weeks. After the completion of part 2 or at the time of relapse, whichever occurred first, patients proceeded to part 3 and received at least two more doses of canakinumab. We evaluated therapeutic responses using disease-activity scores and analysis of levels of C-reactive protein (CRP) and serum amyloid A protein (SAA). RESULTS: In part 1 of the study, 34 of the 35 patients (97%) had a complete response to canakinumab. Of these patients, 31 entered part 2, and all 15 patients receiving canakinumab remained in remission. Disease flares occurred in 13 of the 16 patients (81%) receiving placebo (P<0.001). At the end of part 2, median CRP and SAA values were normal (<10 mg per liter for both measures) in patients receiving canakinumab but were elevated in those receiving placebo (P<0.001 and P=0.002, respectively). Of the 31 patients, 28 (90%) completed part 3 in remission. In part 2, the incidence of suspected infections was greater in the canakinumab group than in the placebo group (P=0.03). Two serious adverse events occurred during treatment with canakinumab: one case of urosepsis and an episode of vertigo. CONCLUSIONS: Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS. (ClinicalTrials.gov number, NCT00465985.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, IL-1RA-blocking Ab (anakinra) and IL-1β-blocking Ab (canakinumab) are already FDA approved as anti-inflammatory biologics for the treatment of rheumatoid arthritis (130) and NLRP3-inflammasome-mediated cryopyrin-associated periodic syndrome (CAPS) (131), respectively.”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [131]
Citations
Cites
Natural History and Outcome in Systemic AA Amyloidosis
Lachmann, H. J., Goodman, H. J. B., Gilbertson, J. A., Gallimore, J. R., Sabin, C. A., Gillmore, J. D., & Hawkins, P. N. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070265 · Cited by 1,032
Self-citationSpectrum of clinical features in Muckle‐Wells syndrome and response to anakinra
Hawkins, P. N., Lachmann, H. J., Aganna, E., & McDermott, M. F. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20033 · Cited by 744
Self-citationHoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577 · cited 2×
“Viral infection 0 2 (13) 0 0 Headache 0 2 (13) 0 3 ( 10 )”
URTICARIA, DEAFNESS, AND AMYLOIDOSIS: A NEW HEREDO-FAMILIAL SYNDROME
(1962) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a066967 · Cited by 372
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
Lachmann, H. J., Lowe, P., Felix, S. D., Rordorf, C., Leslie, K., Madhoo, S., Wittkowski, H., Bek, S., Hartmann, N., Bosset, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082481 · Cited by 312
Self-citationPrimer: inflammasomes and interleukin 1β in inflammatory disorders
Church, L. D., Cook, G. P., & McDermott, M. F. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0681 · Cited by 309
Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Burmester, G. R., Bijlsma, J. W. J., Dougados, M., Emery, P., Keystone, E. C., Klareskog, L., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044941 · Cited by 225
Leslie, K. S., Lachmann, H. J., Bruning, E., McGrath, J. A., Bybee, A., Gallimore, J. R., Roberts, P. F., Woo, P., Grattan, C. E., & Hawkins, P. N. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.12.1591 · Cited by 186 · cited 13×
“Rhinitis 4 (11) 1 (7) 2 (12) 0 Bronchitis 3 (9) 1 ( 7 ) 1 (6) 0”
InfluentialSelf-citationAlten, R., Gram, H., Joosten, L. A., Berg, W. B. V. D., Sieper, J., Wassenberg, S., Burmester, G., van Riel, P., Diaz-Lorente, M., Bruin, G. J., et al. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2438 · Cited by 170
The many worlds of reducing interleukin‐1
Dinarello, C. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21107 · Cited by 104
Research works printed but not linked: 5
- Muckle TJ, 1962, Q J Med, 31, 235
- Lachmann HJ, 2008, Clin Exp Rheumatol, 26, 181
- Kuemmerle-Deschner JB, 2008, Clin Exp Rheumatol, 26, 180
- Kummerle-Deschner J, 2008, Ann Rheum Dis, 67, 104
- Maier J, 2008, J Rheumatol, 35, 939
Cited by
Items 601–700 of 869
Targeting cytokine pathways: the role of biologics in autoinflammatory disorders
Koga, T. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2625277 · Cited by 5
“The advent of molecular-targeted therapies has revolutionized the management of AIDs [11,12].”
Vyzhga, Y., Frenkel, J., Insalaco, A., Antón, J., Koné‐Paut, I., Legger, G. E., Fabio, G., Cattalini, M., Kamphuis, S. S. M., HACHULLA, E., et al. (2024) · Journal of Clinical Immunology · doi:10.1007/s10875-024-01719-4 · Cited by 4
Self-citationZhu, X., Fan, J., Huang, Y., Xu, Y., Yang, Z. P., Weng, R., Luo, Y., Yang, J., & He, T. (2024) · Pediatric Rheumatology · doi:10.1186/s12969-024-01023-w · Cited by 4
“Global assessment was performed with the use of a 5-point scale for disease activity: absent, minimal, mild, moderate, or severe [8].”
MethodNeutrophilic Urticarial Dermatosis: A Window into Systemic Inflammation and Autoimmune Disorders
Cai, X., Zheng, Y., Yang, C., Xu, J., Fang, H., & Qiao, J. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09056-z · Cited by 6
Autoinflammatory syndromes: What a rheumatologist should know
Fedorov, E. S., Salugina, S. O., & Kuzmina, N. N. (2012) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2012-728 · Cited by 4
The Emerging Treatments in Familial Mediterranean Fever
Özdoğan, H., & Uğurlu, S. (2015) · Rare diseases of the immune system · doi:10.1007/978-3-319-14615-7_9 · Cited by 4
Proft, F. N., Fleck, M., Fiehn, C., Schulze‐Koops, H., Witt, M., Dörner, T., & Henes, J. (2017) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-017-0329-x · Cited by 4
Рамеев, В. В., Lysenko, L. V., Bogdanova, M. V., & Moiseev, S. V. (2020) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2020-4-49-60 · Cited by 4
Kormáksson, M., Lange, M. R., Demanse, D., Strohmaier, S., Duan, J., Xie, Q., Carbini, M., Bossen, C., Guettner, A., & Maniero, A. (2024) · Statistics in Medicine · doi:10.1002/sim.10191 · Cited by 6
“…treatment has been shown to be associated with dose-dependent reductions in the inflammatory biomarkers high sensitivity C-Reactive Protein (hsCRP) 23 and interleukin-6 (IL-6), as well as in risk for lung cancer incidence, see CANTOS: Canakinumab Anti-inflammatory Thrombosis Outcome Study.”
Fricke, U., & Schwabe, U. (2010) · Springer eBooks · doi:10.1007/978-3-642-13380-0_2 · Cited by 5
Manners, P. J., & Guttinger, R. (2010) · The Indian Journal of Pediatrics · doi:10.1007/s12098-010-0206-y · Cited by 4
Berman, N., Dunham, J., & Vivino, F. B. (2014) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000190 · Cited by 4
CAPS : Cryopyrin-associated periodic syndrome
Saito, M. K. (2011) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.34.369 · Cited by 4
Subcutaneous administration of a neutralizing IL-1β antibody prolongs limb allograft survival
Hautz, T., Grahammer, J., Moser, D., Eberhart, N., Zelger, B. G., Zelger, B., Blumer, M. J. F., Drasche, A., Wolfram, D., Troppmair, J., et al. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14765 · Cited by 4
Kim, K. Y., Kim, S. Y., Park, S. E., Lee, J., Lee, H., Lee, S., & Kim, J. G. (2018) · Pediatric Infection & Vaccine · doi:10.14776/piv.2018.25.e7 · Cited by 4
Alexeeva, E. I., Vankova, D. D., Soloshenko, M. А., Dvoryakovskaya, T. M., Isaeva, K. B., Denisova, R. V., Mamutova, A. V., Chomahidze, A. M., Mayanskiy, N. A., & Ткаченко, Н. Е. (2019) · Вопросы современной педиатрии · doi:10.15690/vsp.v18i2.2012 · Cited by 4
“При использовании канакинумаба отмечалось увеличение риска развития вирусных и бактериальных инфекций по сравнению с группой контроля (плацебо) [60].”
Familial Mediterranean fever: diagnosis and treatment
Рамеев, В. В., Simonyan, A., Bogdanova, M. V., Kozlovskaya, L. V., & Moiseev, S. V. (2020) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2020-2-56-67 · Cited by 4
“В двойное слепое, плацебо-контролируемое, рандомизированное исследование были включены 35 пациентов с криопирин-ассоциированным периодическим синдромом (КАПС; синдром Макла-Уэллса у 33 и синдром NOMID/CINCA у 2) [72].”
Shangguan, Y., Ding, X., Ma, L., Cai, Y.-X., Xiang, S., Huang, X., Shen, Y., Yu, H., & Zheng, W. J. (2024) · Journal of Immunology Research · doi:10.1155/2024/5722548 · Cited by 4
Die Bedeutung von Biologika bei der Therapie der SoJIA (Morbus Still)
Dückers, G., & Niehues, T. (2010) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-010-0635-z · Cited by 7
A case of cryopyrin-associated periodic syndrome with kidney transplant failure
Imaizumi, R., Ishíi, Y., Miki, K., Shinji, K. U. D. O., Murakami, T., Koyama, I., Nakajima, I., Fuchinoue, S., Kawaguchi, Y., Taniguchi, A., et al. (2014) · CEN Case Reports · doi:10.1007/s13730-014-0129-y · Cited by 4
Interleukin-1 blockade: a magic wand for gout?
Bardin, T. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.213 · Cited by 5
“IL-1 antagonists also include canakinumab, a long-acting monoclonal antibody directed against human IL-1β, which has been shown to be effective in the management of CAP”
BackgroundCarné, X. (2011) · Medicina Clínica · doi:10.1016/s0025-7753(11)70007-0 · Cited by 4
Prolonged, Recurrent, and Periodic Fever Syndromes
Manthiram, K., Edwards, K. M., & Long, S. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-40181-4.00015-3 · Cited by 5
Berg, S., Wekell, P., Fasth, A. L., Hawkins, P. N., & Lachmann, H. J. (2016) · Springer eBooks · doi:10.1007/978-3-662-52909-6_7 · Cited by 4
Self-citationGuidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan
Yokota, S., Nishikomori, R., Takada, H., Kikuchi, M., Nozawa, T., Kanetaka, T., Kizawa, T., Miyamae, T., Mori, M., Heike, T., et al. (2012) · Modern Rheumatology · doi:10.3109/s10165-012-0769-8 · Cited by 4
“However, canakinumab can also suppress physiological inflammation by neutralizing the activity of IL-1b.”
BackgroundInfluentialSalugina, S. O., Fedorov, E. S., Zakharova, E. Y., & Evsikova, М. D. (2015) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2015-1-66-71 · Cited by 4
Bioterapias en dermatología (cáncer no incluido)
Villani, A. P., & Jullien, D. (2016) · EMC - Dermatología · doi:10.1016/s1761-2896(16)79695-6 · Cited by 4
Genetische Fiebersyndrome: Hereditäre rekurrierende (periodische) Fiebersyndrome
Neudorf, U., Lainka, E., Kallinich, T., Holzinger, D., Roth, J., Föll, D., & Niehues, T. (2013) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-012-1061-1 · Cited by 4
A case report of locally invasive Aspergillus fumigatus infection in a patient on canakinumab
Chandrakumaran, A., Malik, M., Stevens, M. P., & Abbate, A. (2018) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/yty098 · Cited by 4
“It is approved for the treatment of cryopyrin-associated periodic syndromes in 2009 by both the Food and Drug Administration and the European Medicines Agency.(1) Canakinumab induced inhibition of inflammation could potentially preserve pancreatic beta cell function and decrease the progression of atherosclerosis in c…”
BackgroundDarbinian, E., Mlaga, K. D., Aranguren, M., Desjardins, A., Martineau, E., Massé, C., Leiding, J. W., Poudrier, J., & Falcone, E. L. (2025) · Blood · doi:10.1182/blood.2025029676 · Cited by 4
Evidenz der Therapie chronisch-entzündlicher Erkrankungen in Kindheit und Adoleszenz mit Biologika
Huppertz, H., & Lehmann, H. (2014) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-014-1398-8 · Cited by 3
Skin Signs of Other Systemic Diseases
Paller, A. S., & Mancini, A. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0412-9.00025-3 · Cited by 3
Monogenic autoinflammatory diseases
Goldbach‐Mansky, R. T., de Jesus, A. A., McDermott, M., & Kastner, D. L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00165-0 · Cited by 3
Gene Regulation in Comorbid Migraine and Myogenic Temporomandibular Disorder Pain
Tao, R., Liu, S., Maltezos, H., & Tao, F. (2025) · Genes · doi:10.3390/genes16121435 · Cited by 3
“Mechanism-based options include direct IL-1 blockade with anakinra, rilonacept, or canakinumab, which show efficacy in IL-1–driven diseases such as Cryopyrin-Associated Periodic Syndromes and recurrent pericarditis [43,44].”
Bélot, A., & Cochat, P. (2010) · Archives de Pédiatrie · doi:10.1016/j.arcped.2010.08.026 · Cited by 3
The laboratory approach in the diagnosis of systemic autoinflammatory diseases
Cantarini, L., Rigante, D., Brizi, M. G., Sebastiani, G. D., Lucherini, O. M., Galeazzi, M., & Frediani, B. (2011) · Reumatismo · doi:10.4081/reumatismo.2011.101 · Cited by 3
Diagnosis and treatment of patients with Cryopyrin-Associated Periodic Syndrome
Козлова, А. Л., Першин, Б. С., Варламова, Т. В., & Shcherbina, A. Y. (2015) · Вопросы современной педиатрии · doi:10.15690/vsp.v14i2.1301 · Cited by 3
Liuqing, Y., Yang, N., Huang, H., Yu, J., Sui, X., Tao, L., Gao, Y., & Liu, Z. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666221007111239 · Cited by 3
Therapeutic targeting of inflammasome signaling by blocking interleukin-1
Coll, R. C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91802-2.00010-4 · Cited by 5
ROLE OF INTERLEUKIN-1 IN OSTEOARTHROSIS AND POSSIBILITIES OF ITS ARREST
Rm, B., & Balabanova, R. M. (2011) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2011-653 · Cited by 4
Cuchacovich, R., García-Valladares, I., & Espinoza, L. R. (2011) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.11.58 · Cited by 3
Prolonged urticaria and fever in a toddler
Broderick, L., Tremoulet, A. H., Burns, J. C., & Hoffman, H. M. (2012) · Allergy and Asthma Proceedings · doi:10.2500/aap.2012.33.3567 · Cited by 3
“Therapies for CAPS primarily target IL-1 and include anakinra (recombinant IL-1 receptor antagonist),(17,18) rilonacept (fusion protein of IL-1 receptor and IL-1 receptor accessory protein),(19,20) and canakinumab (humanized monoclonal antibody to IL-1 ).(21) Studies with IL-1 blockers have consistently shown reductio…”
ResultFamilial Autoinflammatory Syndromes
Simon, A., van der Meer, J. W. M., & Drenth, J. P. H. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00097-8 · Cited by 3
Kötter, I., & Horneff, G. (2010) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-009-0530-7 · Cited by 3
Klinik der autoinflammatorischen Erkrankungen im Kindesalter
Foeldvari, I., & Kümmerle-Deschner, J. B. (2009) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-009-0487-6 · Cited by 3
Tratamiento de los síndromes periódicos asociados a la criopirina (CAPS)
Treviño, S. J., & Polo, E. (2011) · Medicina Clínica · doi:10.1016/s0025-7753(11)70006-9 · Cited by 5
Fièvres récurrentes héréditaires
Stankovic, K., Georgin‐Lavialle, S., & Grateau, G. (2014) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2014.06.005 · Cited by 3
Does this patient have periodic fever syndrome?
Savic, S., & Wood, P. M. D. (2011) · Clinical Medicine · doi:10.7861/clinmedicine.11-4-396 · Cited by 4
Les fièvres récurrentes de l’enfant
Piram, M., & Koné‐Paut, I. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.09.012 · Cited by 3
Corneal response to Canakinumab in Cryopyrin associated periodic fever syndrome
Tsatsos, M., Hawkin, P. N., & Hossain, P. N. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303429 · Cited by 3
Best Practice & Research Clinical
Savic, S., Dickie, L. J., Wittmann, M., & McDermott, M. (2012) · Cited by 3
Mechanism of Action for Therapeutic Antibodies
Zhou, Y., & Marks, J. D. (2016) · Wiley eBooks · doi:10.1002/9781118940648.ch3 · Cited by 3
Laccetta, G., Tutera, M., Miccoli, M., & Consolini, R. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00128 · Cited by 3
Alrahmany, D., & Ghazi, I. M. (2020) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000242 · Cited by 3
“It is used in the treatment of cryopyrin-associated periodic syndromes (CAPS) [28], familial cold auto-inflammatory syndrome (FCAS) and Muckle–Wells Syndrome (MWS), in adults and children greater than 12 years old.”
BackgroundInfluentialMonoclonal Antibodies as Therapeutic Agents
Khan, M. M. (2008) · Springer eBooks · doi:10.1007/978-0-387-77976-8_5 · Cited by 4
Les avancées génétiques dans les maladies auto-inflammatoires
Touitou, I., & Grandemange, S. (2010) · Revue du Rhumatisme Monographies · doi:10.1016/j.monrhu.2010.04.023 · Cited by 3
Shaw, A. C., & Hennekam, R. C. M. (2009) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2009.08.002 · Cited by 3
Schreml, S. (2016) · Wiley eBooks · doi:10.1002/9781118441213.rtd0059 · Cited by 5
Comprehensive Review of Rare Hereditary Autoinflammatory Disorders
Kanazawa, N. (2013) · Journal of Genetic Disorders & Genetic Reports · doi:10.4172/2327-5790.1000106 · Cited by 2
“These facts support a critical role for IL-1β in the development of CAPS [39-41].”
BackgroundHawkins, P. N. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00168-6 · Cited by 2
Self-citationŞatırer, Ö., Henes, J., Henes, M., Benseler, S. M., & Kuemmerle-Deschner, J. B. (2025) · Rheumatology · doi:10.1093/rheumatology/keaf206 · Cited by 2
Self-citationBono, A., Monica, G. L., Alamia, F., Mingoia, F., Martorana, A., & Lauria, A. (2025) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2025.109100 · Cited by 2
Allogeneic hematopoietic cell transplantation for autoinflammatory disorders
Kanegane, H., Miyamoto, S., Kamiya, T., Ohnishi, H., Nishikomori, R., Gennery, A. R., & Mori, T. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04021-0 · Cited by 2
“The quality of life for patients with CAPS has improved with the advent of anti-IL-1β inhibitors [33, 34].”
Antirheumatic drugs and cardiovascular disease in rheumatoid arthritis
Szekanecz, Z., Szűcs, G., & Kerekes, G. (2023) · Rheumatology Forum · doi:10.5603/rf.2023.0010 · Cited by 3
Sears, E. L., & Brooks, S. (2010) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2010.11928615 · Cited by 2
Canakinumab for the treatment of gout
Pazár, B., & So, A. K.-L. (2011) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.11.57 · Cited by 2
Wekell, P., Fasth, A. L., & Berg, S. (2012) · Springer eBooks · doi:10.1007/978-3-642-31785-9_7 · Cited by 2
Treatment of Inflammasome-Related Disorders
Lachmann, H. J. (2011) · Springer eBooks · doi:10.1007/978-3-0348-0148-5_14 · Cited by 2
“Canakinumab has also been licensed for the treatment of CAPS based on a threepart, 48-week double-blind placebo-controlled, randomized withdrawal study [ 12 ].”
MethodSelf-citationTreatment options with biologics for juvenile idiopathic arthritis
Horneff, G. (2011) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.11.26 · Cited by 2
Role of the inflammasome in vascular injury and atherosclerosis
Takahashi, M. (2012) · Inflammation and Regeneration · doi:10.2492/inflammregen.32.112 · Cited by 3
Familial Autoinflammatory Syndromes
Simon, A., van der Meer, J. W. M., & Drenth, J. P. H. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00097-9 · Cited by 2
Kim, P. W., Aksentijevich, I. A., Colburn, N. T., & Kastner, D. L. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00163-9 · Cited by 2
Sleptsova, T. V., Alexeeva, E. I., Савостьянов, К. В., Pushkov, A. A., Bazarova, T. M., Valieva, S. I., Lomakina, O. L., Denisova, R. V., Isaeva, K. B., & Chistyakova, Е. G. (2015) · Педиатрическая фармакология · doi:10.15690/pf.v12i4.1428 · Cited by 2
Sleptsova, T. V., Alexeeva, E. I., Bzarova, T. M., Savostyanov, K. V., Pushkov, A., Isaeva, K. B., Denisova, R. V., & Lomakina, O. L. (2016) · Вопросы современной педиатрии · doi:10.15690/vsp.v15i5.1627 · Cited by 2
Modulating Inflammatory Cytokines
Gresnigt, M. S., & van de Veerdonk, F. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803302-9.00008-7 · Cited by 4
Development of Drugs from Plants
Rieder, M. J., & Bend, J. R. (2012) · Advances in botanical research · doi:10.1016/b978-0-12-394591-4.00010-6 · Cited by 2
Canakinumab for the treatment of TNF-receptor associated periodic syndrome (TRAPS)
Soliani, M., & Cattalini, M. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1379393 · Cited by 2
“Indeed, the efficacy of canakinumab in CAPS has been confirmed in a phase III study, leading to the labeling by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) [44].”
BackgroundBoff, D., Fagundes, C. T., Russo, R. C., & Amaral, F. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-77658-3_2 · Cited by 2
Cryopyrin-Associated Periodic Syndromes (CAPS)
Twilt, M., & Benseler, S. M. (2019) · Springer eBooks · doi:10.1007/978-3-319-96929-9_8 · Cited by 2
Periodic and Non-Periodic Fevers
Gattorno, M. (2019) · Rare diseases of the immune system · doi:10.1007/978-3-030-19055-2_1 · Cited by 2
Yu, Y., Watanabe, R., Shibao, K., Ishii, Y., Nishikomori, R., Heike, T., Fujisawa, Y., & Furuta, J. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15681 · Cited by 2
Cryopyrin-Associated Periodic Syndromes and Treatment Options
Kareva, L., Stavrik, K., & Mironska, K. (2020) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2020.5024 · Cited by 3
Salugina, S. O., & Федоров, Е. С. (2021) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2021-6-95-100 · Cited by 2
Kallinich, T. (2013) · Springer eBooks · doi:10.1007/978-3-642-34728-3_10 · Cited by 2
Prolonged, Recurrent, and Periodic Fever Syndromes
Manthiram, K., Edwards, K. M., & Long, S. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-75608-2.00015-x · Cited by 2
Coexistence of systemic sclerosis and cryopyrin‐associated periodic syndrome
Kuzumi, A., Yoshizaki, A., Matsuda, K. M., Nagai, K., & Sato, S. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17358 · Cited by 2
Şatırer, Ö., Welzel, T., Zapf, B., Benseler, S. M., & Kuemmerle-Deschner, J. B. (2024) · Rheumatology · doi:10.1093/rheumatology/keae340 · Cited by 2
Self-citationSterba, G., & Sterba, Y. (2013) · Dermatologic Clinics · doi:10.1016/j.det.2013.04.007 · Cited by 2
Biologic drugs in pediatric rheumatology
Sen, E. S., & Ramanan, A. V. (2016) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12924 · Cited by 2
Ward, B. R. (2015) · Encyclopedia of Inflammatory Diseases · doi:10.1007/978-3-0348-0620-6_188-3 · Cited by 2
IL-1β-targeted antibody approved for rare autoinflammatory disorders
(2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2953 · Cited by 2
Dhahri, R., Boussaid, S., Ammar, L. B., Fenniche, I., Ayed, H. B., Rahmouni, S., Zouaoui, K., Rekik, S., Amri, K., Sahli, H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1710180 · Cited by 1
CNS-targeted NLRP3 Inhibition by NT-0527 confers therapeutic advantage in a CAPS mouse model
Koller, B. H., Nguyen, M., Doedens, J. R., Harrison, D., Clarke, N. P., Watt, A. P., & Gabel, C. A. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03731-4 · Cited by 2
“CAPS patients are effectively treated with anti-IL-1 biologicals, with early detection and treatment being important for preventing irreversible damage [50–52].”
Interleukin-1: from discovery to therapeutic targeting of the first cytokine
Broderick, L., Kambe, N., & Hoffman, H. M. (2026) · Allergology International · doi:10.1016/j.alit.2026.03.001 · Cited by 4
Li, F., Tan, M., Zhai, R., Ouyang, Y., & Shen, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1938807 · Cited by 1
“Canakinumab has been approved for several in fl ammatory disorders, including cryopyrin-associated periodic syndromes (CAPS) and tumor necrosis factor receptor-associated periodic syndrome (TRAPS) (158, 159).”
Les biothérapies hors AMM dans les maladies systémiques
HACHULLA, E. (2010) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2010.09.015 · Cited by 1
Self-citationInflammasomes and related diseases
Saito, M. K. (2011) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.34.20 · Cited by 2
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
STOCKMAN, J. A. (2011) · Yearbook of Pediatrics · doi:10.1016/s0084-3954(09)79570-3 · Cited by 1
Kulanthaivel, S., Анатольевна, З. А., Sokolova, L. V., Shaduro, D. V., Av, P., & Kaliberdenko, V. B. (2021) · Current Rheumatology Reviews · doi:10.2174/1573397117666211116110833 · Cited by 1
Gravidanza e malattie autoimmuni
Gnerre, G. E. P. (2021) · Italian Journal of Medicine · doi:10.4081/itjm.q.2021.4 · Cited by 1
Metadata
- Authors
- Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N.
- Affiliations
- University College London (GB)
- Universitätsklinikum Tübingen (DE)
- University of California, San Francisco (US)
- Université de Lille (FR)
- Hôpital Necker-Enfants Malades (FR)
- Novartis (Switzerland) (CH)
- Novartis (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-06-04
- Volume
- 360
- Issue
- 23
- Pages
- 2416-2425
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149374693
- Cited by
- 869
- References
- 19
- Citations by year
- 2026: 23 · 2025: 30 · 2024: 31 · 2023: 23 · 2022: 37 · 2021: 40 · 2020: 53 · 2019: 56 · 2018: 34 · 2017: 38 · 2016: 55 · 2015: 67 · 2014: 50 · 2013: 66 · 2012: 73
- FWCI
- 35.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Novartis Pharma
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- canakinumab, cryopyrin-associated periodic syndromes, IL-1β, interleukin-1 receptor antagonist, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, disease flares, C-reactive protein, serum amyloid A, infection risk, urosepsis, vertigo, treatment withdrawal
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Adolescent, Adult, Aged, Antibodies, Monoclonal, Carrier Proteins, Child, Double-Blind Method, Female, Humans, Male, Middle Aged, Mutation, Familial Mediterranean Fever, Interleukin-1beta, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.